Safety assessment of a single and a repeated dose administration of the inactivated vaccine ERAVAC® in dwarf pet rabbits
Publikationer
Kaniner
The main objective of this study was to evaluate the safety and serological response of ERAVAC® (HIPRA, Spain), an inactivated vaccine for preventing the new variant of rabbit haemorrhagic disease virus (RHDV-2), when administered into dwarf pet rabbits.
This study showed that vaccination against RHDV-2 with the licenced vaccine ERAVAC® given to 30- day-old toy dwarf rabbits generates in a low rate transient local signs, while no general signs or important rectal temperature fluctuations were observed. All vaccinated animals responded serologically to ERAVAC® vaccination inducing high antibody response compared to the negative response in the control group.
Download denne artikel
Relaterede produkter
Rekombinant vaccine mod hæmoragisk sygdom (RHD) hos kaniner forårsaget af klassisk (RHDV) og variantstamme (RHDV2), deriblandt meget virulente stammer, som emulsion til injektion.
Inaktiveret vaccine mod hæmoragisk sygdom hos kaniner (virusbetinget blødersygdom), VHD-2, ny variant, i injicerbar emulsion
Inaktiveret vaccine mod hæmoragisk sygdom hos kaniner (virusbetinget blødersygdom), VHD-2, ny variant, i injicerbar emulsion.
Levende heterolog-adjuveret vaccine mod myxomatose, som frysetørret pulver til injektion
Levende homolog vaccine mod myxomatose, som frysetørret pulver til injektion
Inaktiveret vaccine mod hæmoragisk sygdom, som emulsion til injektion
Enrofloxacin, som oral opløsning
Relaterede tjenester
HIPRA University tilbyder uddannelsesprogrammer af høj kvalitet inden for strategiske interesseområder til fagfolk
Få adgang til en avanceret diagnostisk service med maksimal brugerkomfort og pålidelighed
